A moment of truth for global health

A cross cutting approach is needed to meet the challenges of the global financial crisis

[1]  M. Goozner Innovation in Biomedicine: Can Stem Cell Research Lead the Way to Affordability? , 2006, PLoS medicine.

[2]  Fiona E. Murray,et al.  Intellectual property. Enhanced: intellectual property landscape of the human genome. , 2005, Science.

[3]  Thomas H Segall-Shapiro,et al.  Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome , 2010, Science.

[4]  T. Lancet Evaluation: the top priority for global health , 2010, The Lancet.

[5]  Gregory D. Graff,et al.  The global stem cell patent landscape: implications for efficient technology transfer and commercial development , 2007, Nature Biotechnology.

[6]  D. Sridhar,et al.  Global health funding: how much, where it comes from and where it goes. , 2009, Health policy and planning.

[7]  Gareth Jones,et al.  Levels and trends in under-5 mortality, 1990–2008 , 2010, The Lancet.

[8]  M. Heller,et al.  Can Patents Deter Innovation? The Anticommons in Biomedical Research , 1998, Science.

[9]  G. Yamey,et al.  Financing Maternal and Child Health—What Are the Limitations in Estimating Donor Flows and Resource Needs? , 2010, PLoS medicine.

[10]  Wilfried Weber,et al.  Synthetic biology in the analysis and engineering of signaling processes. , 2010, Integrative biology : quantitative biosciences from nano to macro.

[11]  C. Scott,et al.  Challenges to human embryonic stem cell patents. , 2008, Cell stem cell.

[12]  Margaret Chan,et al.  Meeting the Demand for Results and Accountability: A Call for Action on Health Data from Eight Global Health Agencies , 2010, PLoS medicine.

[13]  Katherine Leach-Kemon,et al.  Financing of global health: tracking development assistance for health from 1990 to 2007 , 2009, The Lancet.